AU2003219101A8 - Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein - Google Patents

Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Info

Publication number
AU2003219101A8
AU2003219101A8 AU2003219101A AU2003219101A AU2003219101A8 AU 2003219101 A8 AU2003219101 A8 AU 2003219101A8 AU 2003219101 A AU2003219101 A AU 2003219101A AU 2003219101 A AU2003219101 A AU 2003219101A AU 2003219101 A8 AU2003219101 A8 AU 2003219101A8
Authority
AU
Australia
Prior art keywords
protein
hiv
medicament
administration
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219101A
Other versions
AU2003219101A1 (en
Inventor
Arnaldo Caruso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medestea Internazionale SpA
Original Assignee
Medestea Internazionale SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Internazionale SpA filed Critical Medestea Internazionale SpA
Publication of AU2003219101A1 publication Critical patent/AU2003219101A1/en
Publication of AU2003219101A8 publication Critical patent/AU2003219101A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2003219101A 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein Abandoned AU2003219101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2002A000286 2002-03-29
IT2002TO000286A ITTO20020286A1 (en) 2002-03-29 2002-03-29 USE OF THE PROTEIN P17 ISOLATED FOR THE PREPARATION OF A MEDICATION SUITABLE TO INHIBIT THE IMMUNOSTIMULATING EFFECTS THAT THE PROTEIN PRODUCED D
PCT/EP2003/003177 WO2003082908A2 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Publications (2)

Publication Number Publication Date
AU2003219101A1 AU2003219101A1 (en) 2003-10-13
AU2003219101A8 true AU2003219101A8 (en) 2003-10-13

Family

ID=27638968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219101A Abandoned AU2003219101A1 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Country Status (3)

Country Link
AU (1) AU2003219101A1 (en)
IT (1) ITTO20020286A1 (en)
WO (1) WO2003082908A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20080027A1 (en) 2008-01-15 2009-07-16 Medestea Res & Production S P A SHAPED FORM OF HIV PROTEIN P17.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293792A3 (en) * 1987-06-01 1990-01-17 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus gag-encoded proteins
DK643188A (en) * 1987-11-24 1989-05-25 Smithkline Biolog EXPRESSION OF HIV PROTEINS IN E.COLI AND S.CEREVISIAE
GB9703802D0 (en) * 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
DK1417222T3 (en) * 2001-08-07 2010-12-13 Medestea Res & Production S P A Isolated polypeptides based on the neutralizing epitope of the p17 protein from HIV suitable for vaccines as well as neutralizing anti-p17 antibodies that specifically recognize said neutralizing epitope

Also Published As

Publication number Publication date
AU2003219101A1 (en) 2003-10-13
WO2003082908A2 (en) 2003-10-09
WO2003082908A3 (en) 2004-03-25
ITTO20020286A0 (en) 2002-03-29
ITTO20020286A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
TWI315203B (en) Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments
EA017764B8 (en) Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
IL171683A (en) Immunosuppressant compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
IL221770A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof for preparation of medicaments
IL153920A (en) Somatostatin analogues, processes for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
WO2001032183A3 (en) Pharmaceutical compositions comprising oxcarbazepine
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
IL164373A (en) Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
BR9712523A (en) New heterocyclyl-substituted pyrazole derivatives
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
BR0112962B1 (en) Pharmaceutical compositions comprising hyaluronic acid, glycyrretinic acid and polyvinylpyrrolidone, and their use in the preparation of medicaments.
ES2187300A1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
WO2002074056A3 (en) Allosteric adenosine receptor modulators
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
IL179021A (en) Tetrahydroisoquinoline sulfonamide derivatives, pharmaceutical compositions containing the derivative and the use thereof for the preparation of medicaments
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
IL166098A0 (en) 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them
IL162385A (en) Benzothiazole - and benzoxazole - 4,7 - dione derivatives, uses thereof for the preparation of a medicament, medicaments containing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase